Physician profile

Grace Laast Adofo

Obstetrics & Gynecology · King of Prussia, PA

NPI 1457344269

$2,580.39

in general payments reported to CMS, 2019-2025

24 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $580.89 2019-2022
Amgen INC. $236.12 2019-2022
Therapeuticsmd, INC. $228.80 2020-2022
Daiichi Sankyo INC. $223.61 2019-2022
Myovant Sciences INC. $195.67 2021-2022
Mylan Pharmaceuticals INC. $165.01 2019-2022
Avion Pharmaceuticals $113.63 2019-2022
Pfizer INC. $112.04 2019-2022
Allergan, INC. $105.00 2019-2020
Exeltis, USA INC. $100.28 2019-2022
Coopersurgical, INC. $93.30 2019-2022
Merck Sharp & Dohme LLC $84.26 2019-2020
Millicent US INC $67.58 2019
Amag Pharmaceuticals, INC. $53.45 2019-2020
Hologic Sales and Service, LLC $41.26 2019-2022
Show all 24 companies
CompanyGeneral paymentsYearsTop products
Boston Scientific Corporation $35.64 2019
Avanos Medical $23.56 2019
Urovant Sciences INC $21.75 2022
Duchesnay USA Incorporated $20.00 2019
Mayne Pharma Commercial LLC $19.21 2022
Evofem Biosciences, INC. $18.91 2021
Mission Pharmacal Company $17.23 2019
Agile Therapeutics, INC. $12.17 2021
Ferring Pharmaceuticals INC. $11.02 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Grace Laast Adofo

$2,580.39

in general payments reported 2019-2025

Years
2019-2022
Top company
Abbvie INC.

https://glasscript.com/doctor/66310/grace-laast-adofo

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.